Oncología Hepática
Hospital Clínico Universitario Lozano Blesa
Zaragoza, EspañaPublicacións en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (21)
2024
2023
-
Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis
Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804
2020
-
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Liver International, Vol. 40, Núm. 6, pp. 1467-1476
2018
-
Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study
American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522
2017
-
Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil
Liver Transplantation, Vol. 23, Núm. 4, pp. 498-509
-
Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation
Journal of Hepatology, Vol. 67, Núm. 6, pp. 1168-1176
-
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237
-
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study
Transplant International, Vol. 30, Núm. 10, pp. 1041-1050
-
Human immunodeficiency virus–infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study
Liver Transplantation, Vol. 23, Núm. 5, pp. 645-651
-
Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
Oncotarget, Vol. 8, Núm. 61, pp. 103077-103086
-
Real-world multicenter experience of immunosuppression minimization among 661 liver transplant recipients
Annals of Transplantation, Vol. 22, pp. 265-275
2016
-
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib
Liver International, Vol. 36, Núm. 8, pp. 1206-1212
-
Controlling Diabetes after Liver Transplantation: Room for Improvement
Transplantation, Vol. 100, Núm. 10, pp. e66-e73
-
Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma
Hepatology, Vol. 63, Núm. 2, pp. 488-498
-
Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients
Transplant Infectious Disease, Vol. 18, Núm. 6, pp. 819-831
2015
-
Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients
Clinical Transplantation, Vol. 29, Núm. 8, pp. 667-677
-
Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain
Liver Transplantation, Vol. 21, Núm. 8, pp. 1056-1065
-
V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante
Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637
2014
-
IV Reunión de Consenso de la Sociedad Española de Trasplante Hepático 2012. Excepciones al Model for End-stage Liver Disease en la priorización para trasplante hepático
Gastroenterologia y Hepatologia, Vol. 37, Núm. 2, pp. 83-91